$HAE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HAEMONETICS CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HAEMONETICS CORP. Get notifications about new insider transactions in HAEMONETICS CORP for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 16 2021 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 59.87 | 195 | 11,675 | 38,410 | 38.6 K to 38.4 K (-0.51 %) |
May 18 2021 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 55.97 | 102 | 5,709 | 4,523 | 4.6 K to 4.5 K (-2.21 %) |
May 18 2021 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 55.97 | 219 | 12,257 | 11,118 | 11.3 K to 11.1 K (-1.93 %) |
Apr 20 2021 | HAE | HAEMONETICS CORP | Lingamneni Anila | EVP, Chief Technolo ... | Sell | S | 119.44 | 170 | 20,305 | 3,444 | 3.6 K to 3.4 K (-4.70 %) |
Mar 10 2021 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 120.07 | 107 | 12,847 | 4,380 | 4.5 K to 4.4 K (-2.38 %) |
Mar 10 2021 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 120.07 | 385 | 46,227 | 15,607 | 16 K to 15.6 K (-2.41 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Option Exercise | M | 35.50 | 10,353 | 367,557 | 0 | |
Feb 05 2021 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Sell | S | 134.64 | 10,353 | 1,393,928 | 32,050 | 42.4 K to 32.1 K (-24.42 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Buy | M | 35.50 | 10,353 | 367,557 | 42,403 | 32.1 K to 42.4 K (+32.30 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Option Exercise | M | 35.50 | 10,353 | 367,557 | 0 | |
Feb 05 2021 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Sell | S | 134.64 | 10,353 | 1,393,928 | 32,050 | 42.4 K to 32.1 K (-24.42 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Buy | M | 35.50 | 10,353 | 367,557 | 42,403 | 32.1 K to 42.4 K (+32.30 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Option Exercise | M | 35.50 | 12,180 | 432,420 | 0 | |
Feb 05 2021 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Sell | S | 134.53 | 12,180 | 1,638,575 | 13,755 | 25.9 K to 13.8 K (-46.96 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Buy | M | 35.50 | 12,180 | 432,420 | 25,935 | 13.8 K to 25.9 K (+88.55 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Option Exercise | M | 35.50 | 12,180 | 432,420 | 0 | |
Feb 05 2021 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Sell | S | 134.53 | 12,180 | 1,638,575 | 13,755 | 25.9 K to 13.8 K (-46.96 %) |
Feb 05 2021 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Buy | M | 35.50 | 12,180 | 432,420 | 25,935 | 13.8 K to 25.9 K (+88.55 %) |
Dec 11 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Gift | G | 0.00 | 194,369 | 0 | 170,941 | 365.3 K to 170.9 K (-53.21 %) |
Oct 28 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 106.00 | 100 | 10,600 | 1,749 | 1.8 K to 1.7 K (-5.41 %) |
Oct 28 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 106.00 | 1,161 | 123,066 | 11,337 | 12.5 K to 11.3 K (-9.29 %) |
Oct 26 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 106.58 | 181 | 19,291 | 15,992 | 16.2 K to 16 K (-1.12 %) |
Sep 10 2020 | HAE | HAEMONETICS CORP | Llorens Josep | SVP, Global Manufac ... | Sell | S | 88.71 | 101 | 8,960 | 4,254 | 4.4 K to 4.3 K (-2.32 %) |
Aug 12 2020 | HAE | HAEMONETICS CORP | ABERNATHY ROBERT E | Director | Buy | P | 80.93 | 4,000 | 323,720 | 12,048 | 8 K to 12 K (+49.70 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | Zane Ellen M | Director | Grant | A | 0.00 | 1,983 | 0 | 6,440 | 4.5 K to 6.4 K (+44.49 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | Pomeroy Claire | Director | Grant | A | 0.00 | 1,983 | 0 | 3,939 | 2 K to 3.9 K (+101.38 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Grant | A | 0.00 | 1,983 | 0 | 32,050 | 30.1 K to 32.1 K (+6.60 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Grant | A | 0.00 | 1,983 | 0 | 20,401 | 18.4 K to 20.4 K (+10.77 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Grant | A | 0.00 | 1,983 | 0 | 13,755 | 11.8 K to 13.8 K (+16.85 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | COYLE MICHAEL J | Director | Grant | A | 0.00 | 1,983 | 0 | 2,461 | 478 to 2.5 K (+414.85 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | BURZIK CATHERINE M | Director | Grant | A | 0.00 | 1,983 | 0 | 13,738 | 11.8 K to 13.7 K (+16.87 %) |
Jul 22 2020 | HAE | HAEMONETICS CORP | ABERNATHY ROBERT E | Director | Grant | A | 0.00 | 1,983 | 0 | 8,048 | 6.1 K to 8 K (+32.70 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 92.14 | 1,300 | 119,782 | 16,173 | 17.5 K to 16.2 K (-7.44 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 91.34 | 6,961 | 635,818 | 17,473 | 24.4 K to 17.5 K (-28.49 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 90.32 | 5,175 | 467,406 | 24,434 | 29.6 K to 24.4 K (-17.48 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 87.71 | 10,578 | 927,796 | 29,609 | 40.2 K to 29.6 K (-26.32 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 89.29 | 203 | 18,126 | 40,187 | 40.4 K to 40.2 K (-0.50 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Grant | A | 0.00 | 24,014 | 0 | 40,390 | 16.4 K to 40.4 K (+146.64 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 92.09 | 1,209 | 111,337 | 12,498 | 13.7 K to 12.5 K (-8.82 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 91.38 | 6,146 | 561,621 | 13,707 | 19.9 K to 13.7 K (-30.96 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 90.36 | 5,259 | 475,203 | 19,853 | 25.1 K to 19.9 K (-20.94 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 87.71 | 9,720 | 852,541 | 25,112 | 34.8 K to 25.1 K (-27.91 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 89.29 | 197 | 17,590 | 34,832 | 35 K to 34.8 K (-0.56 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Grant | A | 0.00 | 22,334 | 0 | 35,029 | 12.7 K to 35 K (+175.93 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 91.53 | 3,040 | 278,251 | 1,849 | 4.9 K to 1.8 K (-62.18 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 87.71 | 1,282 | 112,444 | 4,889 | 6.2 K to 4.9 K (-20.77 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 87.16 | 92 | 8,019 | 6,171 | 6.3 K to 6.2 K (-1.47 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 82.29 | 42 | 3,456 | 6,263 | 6.3 K to 6.3 K (-0.67 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Grant | A | 0.00 | 4,322 | 0 | 6,305 | 2 K to 6.3 K (+217.95 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Option Exercise | M | 41.64 | 2,889 | 120,298 | 2,890 | |
Jun 16 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 91.53 | 6,869 | 628,720 | 4,487 | 11.4 K to 4.5 K (-60.49 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 90.00 | 4,005 | 360,450 | 11,356 | 15.4 K to 11.4 K (-26.07 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Buy | M | 41.64 | 2,889 | 120,298 | 15,361 | 12.5 K to 15.4 K (+23.16 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 87.71 | 4,417 | 387,415 | 12,472 | 16.9 K to 12.5 K (-26.15 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 89.29 | 111 | 9,911 | 16,889 | 17 K to 16.9 K (-0.65 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Grant | A | 0.00 | 11,286 | 0 | 17,000 | 5.7 K to 17 K (+197.51 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Sell | S | 87.71 | 45,723 | 4,010,364 | 370,394 | 416.1 K to 370.4 K (-10.99 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Sell | S | 89.29 | 1,294 | 115,541 | 416,117 | 417.4 K to 416.1 K (-0.31 %) |
Jun 16 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Grant | A | 0.00 | 102,064 | 0 | 417,411 | 315.3 K to 417.4 K (+32.37 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Option Exercise | M | 41.64 | 1,106 | 46,054 | 1,107 | |
Jun 10 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 97.19 | 187 | 18,175 | 1,983 | 2.2 K to 2 K (-8.62 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 99.09 | 1,106 | 109,594 | 2,170 | 3.3 K to 2.2 K (-33.76 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Buy | M | 41.64 | 1,106 | 46,054 | 3,276 | 2.2 K to 3.3 K (+50.97 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 97.03 | 83 | 8,053 | 2,170 | 2.3 K to 2.2 K (-3.68 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 97.03 | 324 | 31,438 | 5,714 | 6 K to 5.7 K (-5.37 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 97.03 | 687 | 66,660 | 16,376 | 17.1 K to 16.4 K (-4.03 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 97.03 | 639 | 62,002 | 12,695 | 13.3 K to 12.7 K (-4.79 %) |
Jun 10 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Sell | S | 97.03 | 2,920 | 283,328 | 315,347 | 318.3 K to 315.3 K (-0.92 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 103.37 | 49,105 | 5,075,984 | 49,105 | |
May 19 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Grant | A | 0.00 | 14,510 | 0 | 318,267 | 303.8 K to 318.3 K (+4.78 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Sell | S | 100.44 | 1,008 | 101,244 | 303,757 | 304.8 K to 303.8 K (-0.33 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Option Exercise | A | 103.37 | 1,841 | 190,304 | 1,841 | |
May 19 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Grant | A | 0.00 | 544 | 0 | 2,253 | 1.7 K to 2.3 K (+31.83 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 101.72 | 101 | 10,274 | 1,709 | 1.8 K to 1.7 K (-5.58 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 100.44 | 42 | 4,218 | 1,810 | 1.9 K to 1.8 K (-2.27 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Llorens Josep | SVP, Global Manufac ... | Option Exercise | A | 103.37 | 5,728 | 592,103 | 5,728 | |
May 19 2020 | HAE | HAEMONETICS CORP | Llorens Josep | SVP, Global Manufac ... | Grant | A | 0.00 | 1,692 | 0 | 4,355 | 2.7 K to 4.4 K (+63.54 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Llorens Josep | SVP, Global Manufac ... | Sell | S | 100.44 | 107 | 10,747 | 2,663 | 2.8 K to 2.7 K (-3.86 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Lingamneni Anila | EVP, Chief Technolo ... | Option Exercise | A | 103.37 | 4,092 | 422,990 | 4,092 | |
May 19 2020 | HAE | HAEMONETICS CORP | Lingamneni Anila | EVP, Chief Technolo ... | Grant | A | 0.00 | 1,209 | 0 | 3,390 | 2.2 K to 3.4 K (+55.43 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Option Exercise | A | 103.37 | 5,319 | 549,825 | 5,319 | |
May 19 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Grant | A | 0.00 | 1,572 | 0 | 6,038 | 4.5 K to 6 K (+35.20 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 100.44 | 110 | 11,048 | 4,466 | 4.6 K to 4.5 K (-2.40 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Option Exercise | A | 103.37 | 9,821 | 1,015,197 | 9,821 | |
May 19 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Grant | A | 0.00 | 2,902 | 0 | 17,063 | 14.2 K to 17.1 K (+20.49 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 100.44 | 203 | 20,389 | 14,161 | 14.4 K to 14.2 K (-1.41 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Option Exercise | A | 103.37 | 10,639 | 1,099,753 | 10,639 | |
May 19 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Grant | A | 0.00 | 3,144 | 0 | 13,334 | 10.2 K to 13.3 K (+30.85 %) |
May 19 2020 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 100.44 | 221 | 22,197 | 10,190 | 10.4 K to 10.2 K (-2.12 %) |
Apr 17 2020 | HAE | HAEMONETICS CORP | Lingamneni Anila | EVP, Chief Technolo ... | Option Exercise | A | 103.12 | 7,509 | 774,328 | 7,509 | |
Apr 17 2020 | HAE | HAEMONETICS CORP | Lingamneni Anila | EVP, Chief Technolo ... | Grant | A | 0.00 | 2,181 | 0 | 2,181 | 0 to 2.2 K |
Apr 13 2020 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Option Exercise | M | 45.45 | 6,573 | 298,743 | 0 | |
Apr 13 2020 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 102.00 | 4,329 | 441,558 | 18,418 | 22.7 K to 18.4 K (-19.03 %) |
Apr 13 2020 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 102.00 | 6,573 | 670,446 | 22,747 | 29.3 K to 22.7 K (-22.42 %) |
Apr 13 2020 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Buy | M | 45.45 | 6,573 | 298,743 | 29,320 | 22.7 K to 29.3 K (+28.90 %) |
Apr 13 2020 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Gift | G | 0.00 | 870 | 0 | 22,747 | 23.6 K to 22.7 K (-3.68 %) |
Apr 08 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Option Exercise | M | 34.42 | 2,607 | 89,733 | 0 | |
Apr 08 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 97.12 | 399 | 38,751 | 1,852 | 2.3 K to 1.9 K (-17.73 %) |
Apr 08 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 103.91 | 201 | 20,886 | 2,251 | 2.5 K to 2.3 K (-8.20 %) |
Apr 08 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 101.62 | 2,607 | 264,923 | 2,452 | 5.1 K to 2.5 K (-51.53 %) |
Apr 08 2020 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Buy | M | 34.42 | 2,607 | 89,733 | 5,059 | 2.5 K to 5.1 K (+106.32 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 98.00 | 395 | 38,710 | 14,364 | 14.8 K to 14.4 K (-2.68 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Option Exercise | M | 38.43 | 1,299 | 49,921 | 1,300 | |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Option Exercise | M | 38.43 | 1,299 | 49,921 | 1,300 | |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 99.63 | 207 | 20,623 | 4,383 | 4.6 K to 4.4 K (-4.51 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 99.63 | 207 | 20,623 | 4,383 | 4.6 K to 4.4 K (-4.51 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 98.00 | 118 | 11,564 | 4,590 | 4.7 K to 4.6 K (-2.51 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 98.00 | 118 | 11,564 | 4,590 | 4.7 K to 4.6 K (-2.51 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 100.50 | 1,299 | 130,550 | 4,708 | 6 K to 4.7 K (-21.62 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 100.50 | 1,299 | 130,550 | 4,708 | 6 K to 4.7 K (-21.62 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Buy | M | 38.43 | 1,299 | 49,921 | 6,007 | 4.7 K to 6 K (+27.59 %) |
Mar 10 2020 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Buy | M | 38.43 | 1,299 | 49,921 | 6,007 | 4.7 K to 6 K (+27.59 %) |
Nov 13 2019 | HAE | HAEMONETICS CORP | Bolorforosh Said | EVP, Chief Technolo ... | Sell | S | 118.27 | 339 | 40,094 | 1,977 | 2.3 K to 2 K (-14.64 %) |
Nov 13 2019 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 35.50 | 10,353 | 367,552 | 0 | |
Nov 13 2019 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 45.45 | 6,573 | 298,743 | 0 | |
Nov 13 2019 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 118.26 | 16,926 | 2,001,669 | 48,384 | 65.3 K to 48.4 K (-25.92 %) |
Nov 13 2019 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 35.50 | 10,353 | 367,552 | 65,310 | 55 K to 65.3 K (+18.84 %) |
Nov 13 2019 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 45.45 | 6,573 | 298,743 | 54,957 | 48.4 K to 55 K (+13.59 %) |
Nov 13 2019 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Option Exercise | M | 45.45 | 6,573 | 298,743 | 0 | |
Nov 13 2019 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Sell | S | 118.15 | 6,573 | 776,600 | 30,067 | 36.6 K to 30.1 K (-17.94 %) |
Nov 13 2019 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Buy | M | 45.45 | 6,573 | 298,743 | 36,640 | 30.1 K to 36.6 K (+21.86 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Option Exercise | M | 34.21 | 1,456 | 49,810 | 1,457 | |
Oct 29 2019 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 122.69 | 237 | 29,078 | 2,452 | 2.7 K to 2.5 K (-8.81 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 120.33 | 100 | 12,033 | 2,689 | 2.8 K to 2.7 K (-3.59 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 120.32 | 1,456 | 175,186 | 2,789 | 4.2 K to 2.8 K (-34.30 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Buy | M | 34.21 | 1,456 | 49,810 | 4,245 | 2.8 K to 4.2 K (+52.21 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Option Exercise | M | 34.21 | 11,231 | 384,213 | 11,232 | |
Oct 29 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 122.69 | 1,448 | 177,655 | 10,411 | 11.9 K to 10.4 K (-12.21 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 120.33 | 1,155 | 138,981 | 11,859 | 13 K to 11.9 K (-8.88 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 120.65 | 4,326 | 521,932 | 13,014 | 17.3 K to 13 K (-24.95 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 119.87 | 6,905 | 827,702 | 17,340 | 24.2 K to 17.3 K (-28.48 %) |
Oct 29 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Buy | M | 34.21 | 11,231 | 384,213 | 24,245 | 13 K to 24.2 K (+86.30 %) |
Oct 23 2019 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Grant | A | 0.00 | 1,621 | 0 | 14,759 | 13.1 K to 14.8 K (+12.34 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 124.61 | 1,379 | 171,837 | 4,695 | 6.1 K to 4.7 K (-22.70 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 123.57 | 1,230 | 151,991 | 6,074 | 7.3 K to 6.1 K (-16.84 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 122.37 | 300 | 36,711 | 7,304 | 7.6 K to 7.3 K (-3.95 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 122.34 | 2,295 | 280,770 | 7,604 | 9.9 K to 7.6 K (-23.18 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 124.54 | 5,809 | 723,453 | 13,138 | 18.9 K to 13.1 K (-30.66 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 123.50 | 3,724 | 459,914 | 18,947 | 22.7 K to 18.9 K (-16.43 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 122.50 | 1,100 | 134,750 | 22,671 | 23.8 K to 22.7 K (-4.63 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 122.34 | 8,883 | 1,086,746 | 23,771 | 32.7 K to 23.8 K (-27.20 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 124.59 | 11,448 | 1,426,306 | 13,014 | 24.5 K to 13 K (-46.80 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 124.59 | 11,448 | 1,426,306 | 13,014 | 24.5 K to 13 K (-46.80 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 123.61 | 8,356 | 1,032,885 | 24,462 | 32.8 K to 24.5 K (-25.46 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 123.61 | 8,356 | 1,032,885 | 24,462 | 32.8 K to 24.5 K (-25.46 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 122.72 | 2,900 | 355,888 | 32,818 | 35.7 K to 32.8 K (-8.12 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 122.72 | 2,900 | 355,888 | 32,818 | 35.7 K to 32.8 K (-8.12 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 122.34 | 18,950 | 2,318,343 | 35,718 | 54.7 K to 35.7 K (-34.66 %) |
Oct 10 2019 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 122.34 | 18,950 | 2,318,343 | 35,718 | 54.7 K to 35.7 K (-34.66 %) |
Oct 08 2019 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Grant | A | 0.00 | 5,204 | 0 | 9,899 | 4.7 K to 9.9 K (+110.84 %) |